Harvest Fund Management Co. Ltd Acquires 101 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Harvest Fund Management Co. Ltd increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,192 shares of the biopharmaceutical company’s stock after acquiring an additional 101 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in Regeneron Pharmaceuticals were worth $1,033,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Ronald Blue Trust Inc. grew its holdings in Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 12 shares in the last quarter. IFP Advisors Inc grew its holdings in Regeneron Pharmaceuticals by 9.7% during the 3rd quarter. IFP Advisors Inc now owns 442 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 39 shares in the last quarter. Ritholtz Wealth Management grew its holdings in Regeneron Pharmaceuticals by 18.3% during the 3rd quarter. Ritholtz Wealth Management now owns 510 shares of the biopharmaceutical company’s stock valued at $420,000 after buying an additional 79 shares in the last quarter. Global Retirement Partners LLC grew its holdings in Regeneron Pharmaceuticals by 67.1% during the 3rd quarter. Global Retirement Partners LLC now owns 249 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 100 shares in the last quarter. Finally, Park Place Capital Corp grew its holdings in Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Park Place Capital Corp now owns 95 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is currently owned by company insiders.

Analyst Ratings Changes

REGN has been the subject of a number of research analyst reports. UBS Group lifted their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research report on Wednesday, April 17th. BMO Capital Markets lifted their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Barclays lifted their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a research report on Tuesday, January 23rd. Bank of America lifted their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $976.41.

Regeneron Pharmaceuticals Price Performance

REGN traded up $7.16 on Tuesday, hitting $907.32. 336,829 shares of the company’s stock traded hands, compared to its average volume of 491,297. The company’s 50 day simple moving average is $951.41 and its 200-day simple moving average is $893.20. The firm has a market cap of $99.59 billion, a price-to-earnings ratio of 26.11, a P/E/G ratio of 2.58 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter last year, the company earned $10.96 EPS. The firm’s quarterly revenue was up .6% on a year-over-year basis. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.